Arcus Biosciences Inc. (RCUS)
NYSE: RCUS
· Real-Time Price · USD
9.08
-0.16 (-1.73%)
At close: Jun 16, 2025, 3:59 PM
9.02
-0.66%
After-hours: Jun 16, 2025, 07:51 PM EDT
-1.73% (1D)
| Bid | 8.83 |
| Market Cap | 961.44M |
| Revenue (ttm) | 141M |
| Net Income (ttm) | -391M |
| EPS (ttm) | -4.23 |
| PE Ratio (ttm) | -2.15 |
| Forward PE | -2.03 |
| Analyst | Buy |
| Ask | 9.8 |
| Volume | 464,730 |
| Avg. Volume (20D) | 1,198,198 |
| Open | 9.25 |
| Previous Close | 9.24 |
| Day's Range | 8.92 - 9.25 |
| 52-Week Range | 6.50 - 18.98 |
| Beta | 0.83 |
About RCUS
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol RCUS
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for RCUS stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts1 month ago
-1.35%
Arcus Biosciences shares are trading lower after t...
Unlock content with
Pro Subscription
3 months ago
-16.34%
Arcus Biosciences shares are trading lower after the company announced a $150 million stock offering.
6 days ago · https://www.defenseworld.net
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 7,872 Shares of Arcus Biosciences, Inc. (NYSE:RCUS)UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC decreased its position in Arcus Biosciences, Inc. (NYSE:RCUS – Free Report) by 11.3% during the 4th quarter, according to the...
2 months ago · seekingalpha.com
Arcus Biosciences: A High-Risk Speculation With Multiple Large, Near-Term CatalystsArcus Biosciences presents a high-risk speculation with significant upcoming catalysts, despite recent stock declines and Gilead's exit from the ARC-10 trial. Gilead's continued investment and board p...